Abstract: Objective To investigate the clinical efficacy of aripiprazole in combination with transcranial magnetic stimulation (TMS) in the treatment of schizophrenia and the influence on the level of oxidative stress in patients and the incidence of metabolic syndrome. Methods 90 schizophrenic patients admitted to Xi'an Kangning Psychiatric Hospital from October 2020 to October 2022 were selected as research subjects. The patients were divided into three groups, A, B and C, each with 30 patients using a random number table. Group A was treated with conventional olpin, group B with aripiprazole and group C with aripiprazole combined with transcranial magnetic stimulation. PANSS score, oxidative stress response, glucose and lipid metabolism and the incidence of metabolic syndrome were compared between the three groups. Results There was no significant difference in PANSS scores of positive and negative symptoms between groups A, B and C prior to treatment (P>0.05). After treatment, PANSS levels of positive and negative symptoms were lower in group C than in group A and group B (P<0.05), but there was no significant difference between group A and group B after treatment (P>0.05). There was no significant difference in the concentrations of catalase (CAT), superoxide dismutase (T-SOD) and glutathione peroxidase (GSH- Px) related to oxidative stress in patients in groups B and C prior to treatment (P>0.05). After treatment, CAT levels decreased in the patients in the three groups. The values of T-SOD and GSH Px in Group C were lower than those in Group A and Group B, and the values of T-SOD and GSH-Px in Group C were higher than those in Group A and Group B (P<0.05). However, there was no significant difference in GSH-Px levels after treatment (P>0.05). There was no significant difference between blood sugar, fasting blood sugar, high-density lipoprotein (HDL) and low-density lipoprotein (LDL) in the three pre- and post-treatment groups (P>0.05). After treatment, blood sugar, fasting blood sugar and LDL decreased in both groups and were significantly lower than in group A (P<0.05). The incidence of metabolic syndrome in group B and C was significantly lower than in group A, but there was no significant difference between group B and group C (P>0.05). Conclusion Treatment of aripiprazole combined with transcranial magnetic stimulation for patients with schizophrenia may improve the therapeutic effect of schizophrenia, reduce patients' oxidative stress response and promote glucose and lipid metabolism and reduce the incidence of metabolic syndrome compared to conventional treatment of olpin.

Key words: aripiprazole, Transcranial magnetic stimulation, Schizophrenia, oxidative stress, metabolic syndrome